- Home
- ECBK vs CABA Comparison
ECBK vs CABA Comparison
Compare ECBK & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- CABA
- Stock Information
- Founded
- ECBK 1919
- CABA 2017
- Country
- ECBK United States
- CABA United States
- Employees
- ECBK N/A
- CABA N/A
- Industry
- ECBK Banks
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ECBK Finance
- CABA Health Care
- Exchange
- ECBK Nasdaq
- CABA Nasdaq
- Market Cap
- ECBK 151.0M
- CABA 149.3M
- IPO Year
- ECBK N/A
- CABA 2019
- Fundamental
- Price
- ECBK $15.83
- CABA $1.56
- Analyst Decision
- ECBK
- CABA Strong Buy
- Analyst Count
- ECBK 0
- CABA 7
- Target Price
- ECBK N/A
- CABA $14.43
- AVG Volume (30 Days)
- ECBK 15.7K
- CABA 1.2M
- Earning Date
- ECBK 07-24-2025
- CABA 08-11-2025
- Dividend Yield
- ECBK N/A
- CABA N/A
- EPS Growth
- ECBK 52.06
- CABA N/A
- EPS
- ECBK 0.64
- CABA N/A
- Revenue
- ECBK $27,795,000.00
- CABA N/A
- Revenue This Year
- ECBK N/A
- CABA N/A
- Revenue Next Year
- ECBK N/A
- CABA N/A
- P/E Ratio
- ECBK $25.16
- CABA N/A
- Revenue Growth
- ECBK 12.29
- CABA N/A
- 52 Week Low
- ECBK $12.50
- CABA $0.99
- 52 Week High
- ECBK $16.99
- CABA $7.27
- Technical
- Relative Strength Index (RSI)
- ECBK 47.35
- CABA 42.59
- Support Level
- ECBK $15.97
- CABA $1.58
- Resistance Level
- ECBK $16.44
- CABA $1.74
- Average True Range (ATR)
- ECBK 0.37
- CABA 0.09
- MACD
- ECBK -0.02
- CABA -0.00
- Stochastic Oscillator
- ECBK 5.88
- CABA 0.00
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.